Abstract | BACKGROUND: METHODS: A phase I trial [Clinical trials.gov identifier NCT00731380] to assess the safety and efficacy of nab-paclitaxel+ cisplatin+ 5-fluorouracil (APF) as induction chemotherapy for three cycles, followed by concurrent carboplatin (area-under-curve (AUC) 1.5 weekly) with radiation therapy (RT) (70 Gy/35 fractions), was conducted using a 3+3 design in patients with previously untreated LA-SCCHN. Dose-limiting toxicities (DLTs) included: standard haematologic and non-haematologic toxicities, treatment delays, inability to complete ⩾95% of RT and skin/mucosal toxicity related to RT assessed from day 1 of treatment to 8 weeks after completion of CRT. RESULTS: 17 patients with oropharyngeal cancer were enrolled in three dose levels, with 15 patients evaluable for DLT. The median age was 54 years (range, 44-65 years), 14 patients were male, and 11 patients' tumours were p16 positive and four negative. Grade 3/4 adverse events during APF (%total number of cycles) were hyponatraemia (14%) neutropenia (10%), lymphopaenia (4%) and thrombocytopenia (2%) during 49 evaluable APF cycles. Febrile neutropenia occurred during one cycle of treatment. CONCLUSION: The recommended phase 2 dose of APF is nab-paclitaxel 100mg/m(2) days 1 and 8, cisplatin 75 mg/mg(2) day 1 and 5-fluorouracil 1000 mg/m(2)/day×96 h days 1-4, every 3 weeks, for three cycles prior to CRT.
|
Authors | H H Loong, E Winquist, J Waldron, E X Chen, J Kim, D Palma, N Read, A R A Razak, I Diaz-Padilla, K Chan, A Bayley, M Hossain, L Wang, S Chin, L L Siu, A Hope |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 50
Issue 13
Pg. 2263-70
(Sep 2014)
ISSN: 1879-0852 [Electronic] England |
PMID | 24953566
(Publication Type: Clinical Trial, Phase I, Journal Article)
|
Copyright | Copyright © 2014 Elsevier Ltd. All rights reserved. |
Chemical References |
- Paclitaxel
- Cisplatin
- Fluorouracil
|
Topics |
- Adult
- Aged
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Squamous Cell
(drug therapy, pathology, radiotherapy)
- Chemoradiotherapy
- Cisplatin
(administration & dosage)
- Female
- Fluorouracil
(administration & dosage)
- Head and Neck Neoplasms
(drug therapy, pathology, radiotherapy)
- Humans
- Induction Chemotherapy
- Male
- Middle Aged
- Oropharyngeal Neoplasms
(drug therapy, pathology, radiotherapy)
- Paclitaxel
(administration & dosage)
- Squamous Cell Carcinoma of Head and Neck
|